BACKGROUND: Stereotactic radiosurgery (SRS) is a treatment option for persistent or recurrent acromegaly secondary to a growth hormone secreting pituitary adenoma, but its efficacy is inadequately defined. OBJECTIVE: To assess, in a multicenter, retrospective cohort study, the outcomes of SRS for acromegaly and determine predictors. METHODS: We pooled and analyzed data from 10 participating institutions of the International Gamma Knife Research Foundation for patients with acromegaly who underwent SRS with endocrine follow-up of ≥6 mo. RESULTS: The study cohort comprised 371 patients with a mean endocrine follow-up of 79 mo. IGF-1 lowering medications were held in 56% of patients who were on pre-SRS medical therapy. The mean SRS treatment volume and margin dose were 3.0 cm3 and 24.2 Gy, respectively. The actuarial rates of initial and durable endocrine remission at 10 yr were 69% and 59%, respectively. The mean time to durable remission after SRS was 38 mo. Biochemical relapse after initial remission occurred in 9%, with a mean time to recurrence of 17 mo. Cessation of IGF-1 lowering medication prior to SRS was the only independent predictor of durable remission (P = .01). Adverse radiation effects included the development of ≥1 new endocrinopathy in 26% and ≥1 cranial neuropathy in 4%. CONCLUSION: SRS is a definitive treatment option for patients with persistent or recurrent acromegaly after surgical resection. There appears to be a statistical association between the cessation of IGF-1 lowering medications prior to SRS and durable remission.

3rd Department of Medicine 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Medicine University of Virginia Charlottesville Virginia

Department of Neurological Surgery University of Pittsburgh Pittsburgh Pennsylvania

Department of Neurosurgery Barrow Neurological Institute Phoenix Arizona

Department of Neurosurgery MD Anderson Cancer Center Houston Texas

Department of Neurosurgery New York University Langone Medical Center New York New York

Department of Neurosurgery Ruber Internacional Hospital Madrid Spain

Department of Neurosurgery Taipei Veterans General Hospital Taipei Taiwan

Department of Neurosurgery University of Pennsylvania Philadelphia Pennsylvania USA

Department of Neurosurgery University of Virginia Charlottesville Virginia

Department of Neurosurgery West Virginia University Morgantown West Virginia

Department of Radiation Oncology Beaumont Health System Royal Oak Michigan

Department of Stereotactic and Radiation Neurosurgery Na Homolce Hospital Prague Czech Republic

Division of Neurosurgery Centre de recherche du CHUS University of Sherbrooke Sherbrooke Quebec Canada

Neurosurgery. 2018 Nov 1;83(5):1084. doi: 10.1093/neuros/nyy492. PubMed

Zobrazit více v PubMed

Melmed S. Acromegaly. N Engl J Med. 2006;355(24):2558-2573. PubMed

Katznelson L, Atkinson JL, Cook DM et al. .. American Association of Clinical Endocrinologists Medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract. 2011;17(suppl 4):1-44. PubMed

Mehta GU, Lonser RR. Management of hormone-secreting pituitary adenomas. Neuro Oncol. 2017;19(6):762-773. PubMed PMC

Giustina A, Chanson P, Bronstein MD et al. .. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141-3148. PubMed

Phan K, Xu J, Reddy R, Kalakoti P, Nanda A, Fairhall J. Endoscopic endonasal versus microsurgical transsphenoidal approach for growth hormone-secreting pituitary adenomas-systematic review and meta-analysis. World Neurosurg. 2017;97:398-406. PubMed

Katznelson L, Laws ER Jr, Melmed S et al. .. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-3951. PubMed

Lee CC, Vance ML, Xu Z et al. .. Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab. 2014;99(4):1273-1281. PubMed

Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab. 2011;96(7):1992-2003. PubMed

Franzin A, Spatola G, Losa M, Picozzi P, Mortini P. Results of gamma knife radiosurgery in acromegaly. Int J Endocrinol. 2012;2012:1-6. PubMed PMC

Liu X, Kano H, Kondziolka D et al. .. Gamma knife radiosurgery for clinically persistent acromegaly. J Neurooncol. 2012;109(1):71-79. PubMed

Losa M, Gioia L, Picozzi P et al. .. The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab. 2008;93(7):2546-2552. PubMed

Castinetti F, Taieb D, Kuhn JM et al. .. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab. 2005;90(8):4483-4488. PubMed

Ding D, Starke RM, Sheehan JP. Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy. J Neurooncol. 2014;117(3):445-457. PubMed

Ding D, Yen CP, Starke RM, Lee CC, Sheehan JP. Unyielding progress: recent advances in the treatment of central nervous system neoplasms with radiosurgery and radiation therapy. J Neurooncol. 2014;119(3):513-529. PubMed

Sheehan JP, Pouratian N, Steiner L, Laws ER, Vance ML. Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg. 2011;114(2):303-309. PubMed

Snell JW, Sheehan J, Stroila M, Steiner L. Assessment of imaging studies used with radiosurgery: a volumetric algorithm and an estimation of its error. J Neurosurg. 2006;104(1):157-162. PubMed

Landolt AM, Haller D, Lomax N et al. .. Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metab. 2000;85(3):1287-1289. PubMed

Xu Z, Lee Vance M, Schlesinger D, Sheehan JP. Hypopituitarism after stereotactic radiosurgery for pituitary adenomas. Neurosurgery. 2013;72(4):630-637; 636-637. PubMed

Lee CC, Chen CJ, Yen CP et al. .. Whole-sellar stereotactic radiosurgery for functioning pituitary adenomas. Neurosurgery. 2014;75(3):227-237; discussion 237. PubMed

Nguyen JH, Chen CJ, Lee CC et al. .. Multisession gamma knife radiosurgery: a preliminary experience with a noninvasive, relocatable frame. World Neurosurg. 2014;82(6):1256-1263. PubMed

Iwata H, Sato K, Tatewaki K et al. .. Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity. Neuro-oncol. 2011;13(8):916-922. PubMed PMC

Cifarelli CP, Schlesinger DJ, Sheehan JP. Cranial nerve dysfunction following Gamma Knife surgery for pituitary adenomas: long-term incidence and risk factors. J Neurosurg. 2012;116(6):1304-1310. PubMed

Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH, Jane JA Jr.. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab. 2013;98(8):3190-3198. PubMed

Abu Dabrh AM, Asi N, Farah WH et al. .. Radiotherapy versus radiosurgery in treating patients with acromegaly: a systematic review and meta-analysis. Endocr Pract. 2015;21(8):943-956. PubMed

Placzek H, Xu Y, Mu Y, Begelman SM, Fisher M. Clinical and economic burden of commercially insured patients with acromegaly in the united states: a retrospective analysis. J Manag Care Spec Pharm. 2015;21(12):1106-1114. PubMed PMC

Broder MS, Neary MP, Chang E, Cherepanov D, Katznelson L. Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary. 2014;17(4):333-341. PubMed

Sheehan JP, Kavanagh BD, Asher A, Harbaugh RE. Inception of a national multidisciplinary registry for stereotactic radiosurgery. J Neurosurg. 2016;124(1):155-162. PubMed

Rochette C, Graillon T, Albarel F, et al Increased Risk of Persistent Glucose Disorders After Control of Acromegaly. J Endocr Soc. 2017;1(12):1531-1539. PubMed PMC

Castinetti F, Nagai M, Morange I, et al Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab 2009;94(9):3400-7. PubMed

Mehta GU, Ding D, Patibandla MR, et al Stereotactic Radiosurgery for Cushing Disease: Results of an International, Multicenter Study. J Clin Endocrinol Metab. 2017;102(11):4284-4291. PubMed

Pollock BE, Jacob JT, Brown PD, Nippoldt TB. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg. 2007;106(5):833-8. PubMed

Landolt AM, Haller D, Lomax N, et al Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metab. 2000;85(3):1287-9. PubMed

Acromegaly: Clinical Care in Central and Eastern Europe, Israel, and Kazakhstan

Primary versus postoperative stereotactic radiosurgery for acromegaly: a multicenter matched cohort study

Safety and efficacy of repeat radiosurgery for acromegaly: an International Multi-Institutional Study